

# Colchicine and COVID-19

Pablo Corral, MD<sup>1</sup>, Gonzalo Corral, MD<sup>2</sup>, and Rafael Diaz, MD<sup>3</sup>

The Journal of Clinical Pharmacology  
 2020, 60(8) 978  
 © 2020, The American College of  
 Clinical Pharmacology  
 DOI: 10.1002/jcph.1684

We read with interest the Letter to the Editor titled “Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?” by Nasiripour et al.,<sup>1</sup> in which the authors stated that only 1 phase 3 multicenter, randomized, double-blind, placebo-controlled multicenter study has been assigned to [clinicaltrials.gov](https://clinicaltrials.gov) by the Montreal Heart Institute to investigate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19.<sup>2</sup>

In Argentina, we started COLCOVID Trial to test the effects of colchicine on moderate-/high-risk hospitalized COVID-19 patients with the aim of reducing mortality. This study is a phase 3 multicenter, controlled trial; our protocol was published in [ClinicalTrial.gov](https://clinicaltrials.gov) on March 31, 2020.<sup>3</sup>

Therefore, we would like to affirm that, besides the COLCORONA Trial, there is another study ongoing focused on colchicine in COVID-19.

We appreciate the opportunity to express our comment following the recent publication of the potential role of colchicine in SARS-CoV-2 infection.

## Conflicts of Interest

Pablo Corral reports honoraria for lectures from Amgen, Sanofi, AstraZeneca, and PTC; research grants from Amgen and Genzyme, and personal fees for consultancy from Amgen, Novartis, and Sanofi. Rafael Diaz reports research grants from Sanofi, DalCor, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit and personal fees from Amgen and Cirius.

## References

1. Nasiripour S, Zamani F, Farasatinasab M. Can colchicine as an old anti-inflammatory agent be effective in COVID-19? *J Clin Pharmacol* 2020;60(7):828-829.
2. Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19). <https://clinicaltrials.gov/ct2/show/NCT04322682>. Accessed June 15, 2020.
3. The ECLA PHRI COLCOVID Trial. <https://clinicaltrials.gov/ct2/show/NCT04328480>. Accessed June 15, 2020.

<sup>1</sup>Departamento de Investigacion, Facultad de Medicina, Universidad FASTA, Buenos Aires, Argentina

<sup>2</sup>Servicio de Infectología Clínica 25 de Mayo, Servicio de Infectología, HIGA Alende, Mar del Plata, Buenos Aires, Argentina

<sup>3</sup>Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina

Submitted for publication 3 June 2020; accepted 4 June 2020.

### Corresponding Author:

Pablo Corral, MD, Rawson 1006, Mar del Plata, 7600 Buenos Aires, Argentina  
 Email: [drpablocorral@gmail.com](mailto:drpablocorral@gmail.com)